THE FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS ROLE IN THE PHILADELPHIA POSITIVE CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

被引：0

作者：

Koc, Basak ^{[1
,2
]}

Zulfikar, Bulent ^{[1
,2
]}

机构：

[1] IU Cerrahpasa Med Fac, Istanbul, Turkey

[2] Inst Oncol, Istanbul, Turkey

来源：

PEDIATRIC BLOOD & CANCER | 2015年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

689

引用

页码：84 / 84

页数：1

共 50 条

[31] Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study
Aubert, Lucie
Petit, Arnaud
Bertrand, Yves
Ray-Lunven, Anne-France
Angoso, Marie
Pluchart, Claire
Millot, Frederic
Saultier, Paul
Cheikh, Nathalie
Pellier, Isabelle
Plantaz, Dominique
Sirvent, Anne
Thouvenin-Doublet, Sandrine
Valduga, Julie
Plat, Genevieve
Rialland, Fanny
Henry, Catherine
Esvan, Maxime
Gandemer, Virginie
PEDIATRIC BLOOD & CANCER, 2022, 69 (02)
[32] Cardiotoxicity of Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients
Berisha, Adriatik
Placci, Angelo
Piccaluga, Pier Paolo
HEMATO, 2023, 4 (01): : 68 - 75
[33] Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia
Gruber, Franz
Mustjoki, Satu
Porkka, Kimmo
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (05) : 581 - 597
[34] Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case-control study
Cai, Jiaoyang
Liu, Hu
Chen, Yumei
Yu, Jie
Gao, Ju
Jiang, Hua
Zhai, Xiaowen
Ju, Xiuli
Wu, Xuedong
Wang, Ningling
Tian, Xin
Liang, Changda
Fang, Yongjun
Zhou, Fen
Li, Hong
Sun, Lirong
Yang, Liangchun
Guo, Jing
Liu, Aiguo
Li, Chi-kong
Zhu, Yiping
Tang, Jingyan
Yang, Jun J.
Shen, Shuhong
Cheng, Cheng
Pui, Ching-Hon
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 38
[35] Tyrosine kinase inhibitors in adult Philadelphia chromosome positive acute lymphoblastic leukemia: before, after, or instead of allogeneic stem cell transplantation
Lussana, Federico
Rambaldi, Alessandro
DRUGS AND CELL THERAPIES IN HEMATOLOGY, 2016, 4 (01): : 22 - 30
[36] Comparison of clinical efficacy between first-generation and second-generation tyrosine kinase inhibitors based regimen in the treatment of patients with BCR-ABL positive acute lymphoblastic leukemia
刘莹
ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (04) : 230 - 230
[37] PHILADELPHIA-CHROMOSOME POSITIVE CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
PRIEST, JR
ROBISON, LL
MCKENNA, RW
LINDQUIST, LL
WARKENTIN, PI
LEBIEN, TW
WOODS, WG
KERSEY, JH
COCCIA, PF
NESBIT, ME
BLOOD, 1980, 56 (01) : 15 - 22
[38] Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
Steinberg, Michael
CLINICAL THERAPEUTICS, 2007, 29 (11) : 2289 - 2308
[39] Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
Klaus Hirschbühl
Myriam Labopin
Mohamed Houhou
Ludovic Gabellier
Hélène Labussière-Wallet
Bruno Lioure
Dietrich Beelen
Jan Cornelissen
Gerald Wulf
Pavel Jindra
Hervé Tilly
Jakob Passweg
Riita Niittyvuopio
Gesine Bug
Christoph Schmid
Arnon Nagler
Sebastian Giebel
Mohamad Mohty
Bone Marrow Transplantation, 2021, 56 : 1190 - 1199
[40] Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
Litzow, Mark R.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (04) : 357 - 360

← 1 2 3 4 5 →